Table 2. BRAF mutations analysis in 201 consecutive samples analyzed by Sanger sequencing and ASLNAqPCR.

Tissue	BRAF		No amplifiable DNA
	Mutated by SSEQ (%)	Mutated by ASLNA (%)	SSEQ (%)	ASLNA (%)
COLON CRC ( n = 159)	15/153 (9.8)	19/153 (12.4)	6/159 (3.8)	6/159 (3.8)
Primary (n = 114)	13/109 (11.9)	15/109 (13.8)	5/114 (4.4)	5/114 (4.4)
Metastatic (n = 45)	2/44 (4.5)	4/44 (9.1)	1/45 (2.2)	1/45 (2.2)
LUNG NSCLC (n = 24)	0/24 (0)	0/24 (0)	0/24 (0)	0/24 (0)
Primary (n = 17)	0/17 (0)	0/17 (0)	0/17 (0)	0/7 (0)
Metastatic (n = 7)	0/7 (0)	0/7 (0)	0/7 (0)	0/7 (0)
PANCREAS (n = 11)	0/10 (0)	0/10 (0)	1/11 (9.1)	1/11 (9.1)
Carcinoma (n = 5)	0/5 (0)	0/5 (0)	0/5 (0)	0/5 (0)
Cyst Fluid (n = 6)	0/5 (0)	0/5 (0)	1/6 (16.7)	1/6 (16.7)
THYROID (n = 7)	0/7 (0)	1/7 (1.4)	0/7 (0)	0/7 (0)
PTC-Classic (n = 3)	0/3 (0)	1/3 (0)	0/3 (0)	0/3 (0)
PTC-Others (n = 4)	0/4 (0)	0/4 (0)	0/3 (0)	0/3 (0)

SSEQ, Sanger sequencing; ASLNA, allele specific quantitative PCR using 3′-locked nucleic acid modified primers (ASLNAqPCR); CRC, colonic adenocarcinoma; NSCLC, lung adenocarcinoma; PTC, papillary thyroid carcinoma.